Abbott Laboratories (NYSE:ABT) had its hold rating reaffirmed by analysts at BTIG Research.
Adaptimmune Therapeutics (NASDAQ:ADAP) had its buy rating reiterated by analysts at Raymond James. They currently have a $20.00 price target on the stock. The analysts wrote, “Benjamin observed: Benjamin observed: We are maintaining our Outperform rating and increasing our price target to $20 (previously was $11) for ADAP given our increasing confidence in the company’s TCR franchise. Yesterday, the company reported 4Q17 financial results and provided an update on its TCR programs. Key takeaways include: 1) three partial responses (PRs) achieved by the NY- ESO TCR among four patients with myxoid/ round cell liposarcoma (MRCLS); 2) a slew of additional data readouts expected throughout 2018, including the first efficacy results from the MAGE-A10 and MAGE-A4 studies anticipated in 2H18; and 3) a cash runway through early 2020. With growing evidence from the NY-ESO TCR, multiple clinical data readouts expected from the wholly owned assets in 2018, a marquee partner like GlaxoSmithKline to move the NY-ESO program into pivotal studies, and a strong cash position of $188 million (pro forma), we continue to recommend shares of Adaptimmune to long-term, risk tolerant investors.”
Baker Hughes, a GE (NYSE:BHGE) had its buy rating reaffirmed by analysts at Royal Bank of Canada. They currently have a $35.00 price target on the stock.
Tableau Software (NYSE:DATA) had its buy rating reiterated by analysts at Barclays. They currently have a $102.00 target price on the stock.
Dynavax Technologies (NASDAQ:DVAX) was downgraded by analysts at BidaskClub from a buy rating to a hold rating.
ManpowerGroup (NYSE:MAN) had its buy rating reissued by analysts at Nomura. The firm currently has a $134.00 price target on the stock.
MicroStrategy (NASDAQ:MSTR) had its buy rating reiterated by analysts at Mizuho. Mizuho currently has a $200.00 target price on the stock. The analysts wrote, “We think expectations are modest; however, we note the potential for recent changes in sales leadership to muddy n-t results. Full-year growth and profitability estimates appear largely de-risked; we expect commentary on the call to remain constructive on execution initiatives with a potential 2H pick-up. Maintain Buy rating and $200 PT on favorable risk/reward.””
MGIC Investment (NYSE:MTG) had its buy rating reissued by analysts at BTIG Research. BTIG Research currently has a $18.00 price target on the stock.
Nutanix (NASDAQ:NTNX) had its buy rating reiterated by analysts at Stifel Nicolaus. The firm currently has a $64.00 target price on the stock.
Procter & Gamble (NYSE:PG) had its hold rating reaffirmed by analysts at Barclays.
Regions Financial (NYSE:RF) had its neutral rating reissued by analysts at Keefe, Bruyette & Woods.
Sientra (NASDAQ:SIEN) was upgraded by analysts at BidaskClub from a sell rating to a hold rating.
SunTrust Banks (NYSE:STI) had its buy rating reiterated by analysts at Piper Jaffray. They currently have a $75.00 target price on the stock.
Webster Bank (NYSE:WBS) had its hold rating reissued by analysts at Barclays. Barclays currently has a $65.00 target price on the stock.
Receive News & Ratings for Abbott Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abbott Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.